OBJECTIVES:  Identify factors associated with current advanced therapy (AT) use among patients with rheumatoid arthritis (RA). METHODS:  Data were obtained from the US 2016 Adelphi RA Disease Specific Programme. Rheumatologists (HCP, N=85) provided details about their RA patients (N=1,003) and patients voluntarily completed a self-reported questionnaire (N=639). The analysis sample consisted of patients with complete data on variables of interest (N=327). AT for RA was defined as current use of a tumor necrosis factor inhibitor (TNFi), non-TNFi, or Janus kinase inhibitor (JAKi). Multivariable logistic regression was used to examine predictors of current AT vs. conventional disease-modifying antirheumatic drug (cDMARD) use. The following variables were included based on clinical relevance and univariable analyses: age, sex, RA duration at initiation of current therapy, accepting of injectables (IV or SC) therapy (HCP-reported); treatment goal set, concern with side effects, cost factor in treatment decision (patient-reported); disease severity prior to treatment initiation, patient engagement/willingness to change therapy (HCP- and patient-reported). Odds ratios (OR) and 95% confidence intervals (95%CI) were assessed. RESULTS:  Mean±SD age was 54±15y, 74% were female, with duration of RA 88±96 months, 70% were current users of AT [TNFi (69%), non-TNFi (21%), JAKi (10%)], and most (63%) were 1^st-line AT. Current AT use was more common among patients whose HCP classified them as accepting of injectable therapies (OR=2.29, 95%CI: 1.21–4.31) and when patients expressed willingness to change therapy to meet treatment goals (OR=2.33, 95%CI: 1.33–4.07). In contrast, HCP perception of patients’ engagement/willingness to change therapy was unrelated to current AT use (OR=1.15, 95%CI: 0.64–2.06). CONCLUSIONS:  Key predictors of AT use are patient willingness to switch and perceived acceptance of injectable therapies. This suggests that the patient voice is important in uptake of AT and may help to counter any inertia in appropriate treatment escalation.